Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Dysbiosis or ARO Clearance
NCT03834051Terminated
- Sponsor
- Island Health
- Start
- Feb 2019
- Primary completion
- Jun 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Open-label, single-arm trial of allogeneic fecal microbiota in ulcerative colitis (UC), Crohn's disease, irritable bowel syndrome (IBS) and 2 more, sponsored by Island Health. Primary endpoints: Efficacy of FMT in Active Ulcerative Colitis at 1 year, Efficacy of FMT for Irritable Bowel Syndrome at 1 year and 3 more. Started Feb 2019; status: terminated.
02
Drugs
allogeneic fecal microbiota
03
Conditions
ulcerative colitis (UC)Crohn's diseaseirritable bowel syndrome (IBS)microscopic colitis (MC)colonization
Beyond the preview
Go deeper on NCT03834051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834051.